Carbamazepine and oxcarbazepine

Wyllie's Treatment of Epilepsy: Principles and Practice: Fifth Edition

Volumn , Issue , 2012, Pages 614-621

  Guerreiro, Carlos A M ^a   Guerreiro, Marilisa M ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84973432293     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (50)

1. Brodie MJ, Ditcher MA. Antiepileptic drugs. N Engl J Med. 1996;334:168-175.
2. Macdonald RL. Carbamazepine. Mechanism of action. In: Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic Drugs. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:227-235.
3. McLean MJ. Oxcarbazepine. Mechanism of action. In: Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic Drugs. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:451-458.
4. Spina E. Carbamazepine. Chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic Drugs. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002: 236-246.
5. Bourgeois BFD. Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed? Neurology. 2000;55(suppl 3):S11-S16.
6. Bourgeois BFD. Pharmacokinetics and pharmacodynamics of antiepileptic drugs. In: Wyllie E, ed. The Treatment of Epilepsy: Principles and Practice. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:729-739.
7. Novartis Pharmaceutical Corporation. Trileptal (oxcarbazepine) prescription information [online]. 2009. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/trileptal.pdf. Accessed January 24, 2009.
8. Wurden CJ, Levy RH. Carbamazepine: interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic Drugs. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:247-261.
9. Bourgeois BFD. Important pharmacokinetic properties of antiepileptic drugs. Epilepsia. 1995;36(suppl 5):S1-S7.
10. Loiseau P. Carbamazepine. Clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic Drugs, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:262-272.
11. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures. N Engl J Med. 1992;327:765-771.
12. Mattson RH, Cramer JA, Collins JK, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;313:145-151.
13. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64(11):1868-1873.
14. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. 2003;107:165-175.
15. Kälviäinen R, Aikia M, Saukkonen AM, et al. Viagabatrin versus carbamazepine monotherapy in patients with newly diagnosed epilepsy: a randomized controlled study. Arch Neurol. 1995;52:989-996.
16. Brodie MJ, Wroe SJ, Dean AD, et al. Efficacy and safety of remacemide versus carbamazepine in newly diagnosed epilepsy: comparison by sequential analysis. Epilepsy Behav. 2002;3:140-146.
17. Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology. 1998;51:1282-1288.
18. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68(6):402-408.
19. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094-1120.
20. Gilliam F. Optimizing health outcomes in active epilepsy. Neurology. 2002;58(suppl 5):S9-S20.
21. Pellock JM. Carbamazepine side effects in children and adults. Epilepsia. 1987;28 (suppl 3):S64-S70.
22. Holmes GL. Carbamazepine. Adverse effects. In: Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic Drugs. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:285-297.
23. Schlienger RG, Shear NH. Antiepileptic drug hypersensitivity syndrome. Epilepsia. 1998;39(suppl 7):S3-S7.
24. Bohan KH, Mansuri TF, Wilson NM. Anticonvulsivant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy. 2007;27(10):1425-1439.
25. Blackburn SC, Oliart AD, Garcia Rodriguez LA, et al. Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy. 1998;18:1277-1283.
26. Herman S. Sex hormones and epilepsy: no longer just for women. Epilepsy Curr. 2008;8(1):6-8.
27. Yerby MS. Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation. Epilepsia. 2003;44(suppl 3):S33-S40.
28. Meador K. Effects of in utero antiepileptic drug exposure. Epilepsy Curr. 2008;8(6):143-147.
29. Bergen DC. Maintaining strong bones: strong opinions, little evidence. Epilepsy Curr. 2007;7(5):123-124.
30. Abou-Khalil BW. When should clinicians worry about bone density for patients with epilepsy? Epilepsy Curr. 2008;8(6):148-149.
31. The Tegretol OROS Osmotic Release Delivery System Study Group. Double-blind crossover comparison of Tegretol-XR and Tegretol in patients with epilepsy. Neurology. 1995;45:1703-1707.
32. Information for healthcare professionals. Carbamazepine (market as Carbatrol, Equetro, Tegretol and generics). FDA Alert 12/12/07, updated 1/31/08. Available at: http:www.fda.gov/cder/drug/InfoSheet/HCP/carbamazepineHCP.htm. Accessed January 10, 2009.
33. Faigle JW, Menge GP. Metabolic characteristics of oxcarbazepine and their beneficial implications for enzyme induction and drug interactions. Behav Neurol. 1990;3:21-30.
34. Bialer M. Oxcarbazepine: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic Drugs. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002: 459-465.
35. Gram L. Oxcarbazepine. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia, PA: Lippincott-Raven Publishers; 1997:1541-1546.
36. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2:347-356.
37. Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 1989;3:70-76.
38. Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. 1997;27:195-204.
39. Christe W, Krämer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. 1997;26:451-460.
40. Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology. 2000;54:2245-2251.
41. Sachdeo R, Beydoun A, Schachter S, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology. 2001;57:864-871.
42. Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology. 1999;52:732-737.
43. Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. 1997;27:205-213.
44. Beydoun A, Nasreddine WM, Albini F. Oxcarbazepine. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:1593-1598.
45. Krämer G. Oxcarbazepine: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, et al., eds. Antiepileptic Drugs. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:479-486.
46. Pedersen B, D'Souza J. Oxcarbazepine (Trileptal) therapy results in no clinically significant changes in weight. Epilepsia. 2002;43(suppl 8):149. Abstract.
47. Pennell PB. Using current evidence in selecting antiepileptic drugs for use during pregnancy. Epilepsy Curr. 2005;5(2):45-51.
48. Aldenkamp AP, Krom MD, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia. 2003;44:21-29.
49. Vendrame M, Khurana DS, Cruz M, et al. Aggravation of seizures and/or EEG features in children treated with oxcarbazepine monotherapy. Epilepsia. 2007;48(11):2116-2120.
50. Sachdeo RC, Gates JR, Bazil CW, et al. Improved quality of life in patients with partial seizures after conversion to oxcarbazepine monotherapy. Epilepsy and Behavior. 2006;(9):457-463.